The Coca-Cola Co, Abbott Laboratories Beat Estimates

0
The Coca-Cola Co, Abbott Laboratories Beat Estimates
Couleur / Pixabay

Coca-Cola and Abbott Laboratories released their latest earnings reports before opening bell this morning. Coca-Cola posted adjusted earnings of 63 cents per share and revenue of $12.2 billion, a decline from last year’s $12.6 billion. Analysts had been expecting earnings of 60 cents per share and $12.1 billion in revenue.

Play Quizzes 4

Abbott Laboratories posted earnings of 52 cents per share on revenue of $5.2 billion. Analysts had been expecting earnings of 50 cents per share on $5.15 billion in revenue. GAAP earnings were also 52 cents per share.

London Value Investor Conference: Joel Greenblatt On Value Investing In 2022

The first London Value Investor Conference was held in April 2012 and it has since grown to become the largest gathering of Value Investors in Europe, bringing together some of the best investors every year. At this year’s conference, held on May 19th, Simon Brewer, the former CIO of Morgan Stanley and Senior Adviser to Read More

Key metrics from Coca-Cola’s earnings report

Coca-Cola’s reported earnings were 71 cents per share compared to last year’s 58 cents. Unit case volume increased 2%, and the company said it gained value and volume share in nonalcoholic ready-to-drink beverages. Coca-Cola recorded a 1% increase in sparkling beverages units and a 5% increase in still beverages. Reported volume of concentrate sales increased 3%, and price per mix grew 1%.

The company reported a headwind of 11 points on operating income and 6 points on income before taxes and earnings per share due to currencies.

As of this writing, shares of Coca-Cola were up 0.8% at $41.55 per share.

Key metrics from Abbott Laboratories

Abbott Laboratories recorded a 6.3% operational increase in Nutrition sales, which rose to $1.7 billion, including $988 million internationally and $729 million in U.S. sales. The Diagnostics division recorded a 9% operational increase in sales to $1.8 billion, including $350 million in U.S. sales and $827 million in international sales. The Established Pharmaceuticals business saw a 46% operational increase in sales, bringing the segment’s revenue to $977 million. Abbott’s Medical Devices business saw a 3.1% operational increase, bringing sales for the division to $1.3 billion, including $505 million in the U.S. and $784 million internationally.

Abbott Laboratories maintained its full year guidance for adjusted earnings per share, which is between $2.10 and $2.20 per share. The drug maker still expects GAAP earnings of between $1.50 and $1.60 per share for continuing operations.

As of this writing, shares of Abbott Laboratories were down 1.04% at $49.25 per share.

Updated on

Michelle Jones is editor-in-chief for ValueWalk.com and has been with the site since 2012. Previously, she was a television news producer for eight years. She produced the morning news programs for the NBC affiliates in Evansville, Indiana and Huntsville, Alabama and spent a short time at the CBS affiliate in Huntsville. She has experience as a writer and public relations expert for a wide variety of businesses. Email her at Mjones@valuewalk.com.
Previous article Looking At Newly Owned Activist Stocks
Next article S&P 500 Intra-Year Declines [Chart]

No posts to display